Vivozon Pharmaceutical

At a glance

Vivozon Pharmaceutical filed 100 disclosures in the last 12 months, including 33 insider, 17 5% holder and 1 buyback. The most recent key filing was on Oct 6.

Revenue for 2025 was ₩59.3B, down 32.3% on 2024. It made an operating loss of ₩19.2B. Debt was 128% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩27.4B and operating loss of ₩5B.

The 2025 annual report lists 292 employees with an average tenure of 4.6 years and average pay of ₩52.8M, #1323 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩62.6M each on average. It paid no cash dividend for 2025. ㈜비보존홀딩스 and related parties held 35.16% at year end.

From the 2025 annual report

Staff: 292 (188 men, 104 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩15.4B. Directors and auditors: 5, paid ₩312.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜비보존홀딩스 holds 24.87%; with 3 related parties the group holds 35.16% of common shares at year end (from 37.19% at the start of the year).

Source: 2025 annual business report (DART). How figures are combined

Financial summary